当前位置： SCI文献检索 > BRITISH JOURNAL OF CANCER期刊下所有文献 > Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.

Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.

Abstract：

:Cellular mechanisms that account for tumour osteolysis associated with Ewing's sarcoma are uncertain. Osteoclasts are marrow-derived multinucleated cells (MNCs) that effect tumour osteolysis. Osteoclasts are known to form from macrophages by both receptor activator for nuclear factor-kappaB (RANK) ligand (RANKL)-dependent and -independent mechanisms. In this study, our aim has been to determine whether tumour-associated macrophages (TAMs) isolated from Ewing's sarcoma are capable of differentiating into osteoclasts and to characterise the cellular and humoral mechanisms whereby this occurs. Tumour-associated macrophages were isolated from two Ewing's sarcomas and cultured on both coverslips and dentine slices for up to 21 days with soluble RANKL and macrophage colony stimulating factor (M-CSF). Osteoclast formation from TAMs (CD14+) was evidenced by the formation of tartrate-resistant acid phosphatase (TRAP) and vitronectin receptor (VNR)-positive MNCs, which were capable of carrying out lacunar resorption. This osteoclast formation was inhibited by the addition of bisphosphonates. Both Ewing's sarcoma-derived fibroblasts and some bone stromal cells expressed RANKL and supported osteoclast formation by a contact-dependent mechanism. We also found that osteoclast differentiation occurred when Ewing's TAMs were cultured with tumour necrosis factor (TNF)-alpha in the presence of M-CSF and that TC71 Ewing's sarcoma cells stimulated osteoclast formation through the release of a soluble factor, the action of which was abolished by an antibody to TNF-alpha. These results indicate that TAMs in Ewing's sarcoma are capable of osteoclast differentiation by both RANKL-dependent and TNF-alpha-dependent mechanisms and that Ewing's sarcoma cells produce osteoclastogenic factor(s). Our findings suggest that anti-resorptive and anti-osteoclastogenic therapies may be useful in inhibiting the osteolysis of Ewing's sarcoma.

journal_name

Br J Cancer

journal_title

British journal of cancer

authors

Lau YS,Adamopoulos IE,Sabokbar A,Giele H,Gibbons CL,Athanasou NA

doi

10.1038/sj.bjc.6603774

subject

Has Abstract

pub_date

2007-06-04 00:00:00

pages

1716-22

issue

eissn

0007-0920

issn

1532-1827

pii

6603774

journal_volume

pub_type

杂志文章

在线工具

Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.